ABT-072
Sponsors
Abbott, AbbVie (prior sponsor, Abbott)
Conditions
Chronic Hepatitis C InfectionHCVHCV InfectionHepatitis CHepatitis C Genotype 1Hepatitis C Virus Infection
Phase 1
A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults
CompletedNCT00752687
Start: 2008-09-30Updated: 2010-10-21
A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C
CompletedNCT00890318
Start: 2009-04-30Updated: 2010-10-21
Evaluation of the Bioavailability of Two ABT-072 Tablet Formulations as Compared to ABT-072 Capsule Formulation
CompletedNCT00947440
Start: 2009-07-31Updated: 2010-10-21
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
CompletedNCT00982826
Start: 2009-09-30End: 2010-01-31Updated: 2010-10-21
A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults
CompletedNCT01081483
Start: 2010-03-31Updated: 2010-10-25
Phase 2
A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies
CompletedNCT00872196
Start: 2009-04-30End: 2010-04-30Updated: 2013-04-01
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
CompletedNCT01074008
Start: 2010-03-31End: 2012-01-31Updated: 2015-01-08
A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV)
CompletedNCT01221298
Start: 2010-10-31End: 2012-04-30Updated: 2015-01-08